financetom
Business
financetom
/
Business
/
DoubleVerify Q1 Net Income Declines, Revenue Rises; Q2 Revenue Outlook Set -- Shares Fall After Hours
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
DoubleVerify Q1 Net Income Declines, Revenue Rises; Q2 Revenue Outlook Set -- Shares Fall After Hours
May 7, 2024 3:03 PM

05:49 PM EDT, 05/07/2024 (MT Newswires) -- DoubleVerify Holdings ( DV ) reported Q1 net income late Tuesday of $0.04 per diluted share, down from $0.07 a year earlier.

Analysts polled by Capital IQ expected $0.02.

Revenue for the quarter ended March 31 was $140.8 million, up from $122.6 million a year earlier.

Analysts surveyed by Capital IQ expected $138.2 million.

The company said it expects Q2 revenue of $152 million to $156 million. Analysts polled by Capital IQ expect $158.4 million.

DoubleVerify ( DV ) said it is decreasing full-year 2024 revenue estimates in the range of $663 million to $675 million from an earlier outlook of $688 million to $704 million. Analysts polled by Capital IQ expect $695.9 million.

The company shares were down more than 36% in after-hours activity.

Price: 19.50, Change: -11.07, Percent Change: -36.22

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Tesla investors lose bid for new US trial over Musk's 2018 tweets
Tesla investors lose bid for new US trial over Musk's 2018 tweets
Nov 9, 2024
(Reuters) - A U.S. appeals court on Wednesday upheld a jury's verdict clearing Tesla CEO Elon Musk and his company of liability over allegations they misled investors when the billionaire posted on social media in 2018 that he had funding secured to take the electric car company private. The San Francisco-based 9th U.S. Circuit Court of Appeals rejected arguments by...
Ionis Reports Late-Stage Trial Design in Angelman Syndrome
Ionis Reports Late-Stage Trial Design in Angelman Syndrome
Nov 9, 2024
02:29 PM EST, 11/06/2024 (MT Newswires) -- Ionis Pharmaceuticals ( IONS ) said Wednesday it has aligned with the US Food and Drug Administration on ION582, its investigational medicine for the treatment of people living with Angelman syndrome. We will enroll a broad group of individuals living with AS in the global pivotal Phase 3 trial, planned to begin in...
Market Chatter: Qualys Exploring Potential Sale
Market Chatter: Qualys Exploring Potential Sale
Nov 9, 2024
02:24 PM EST, 11/06/2024 (MT Newswires) -- Qualys ( QLYS ) is exploring options that include a possible sale after receiving takeover interest, Bloomberg reported Wednesday, citing people familiar with the matter. The cybersecurity company did not immediately reply to a request for comment from MT Newswires. (Market Chatter news is derived from conversations with market professionals globally. This information...
BRIEF-Cybersecurity Company Qualys Is Said To Explore Potential Sale- Bloomberg News
BRIEF-Cybersecurity Company Qualys Is Said To Explore Potential Sale- Bloomberg News
Nov 9, 2024
Nov 6 (Reuters) - * CYBERSECURITY COMPANY QUALYS IS SAID TO EXPLORE POTENTIAL SALE- BLOOMBERG NEWS Source https://tinyurl.com/38de9w2s ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved